Almirall Prodesfarma, S.A.
General Mitre, 151
Barcelona
08022
Tel: 34-932-913-000
Fax: 34-932-913-180
Website: http://www.almirallprodesfarma.com/
34 articles about Almirall Prodesfarma, S.A.
-
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
3/13/2024
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013.
-
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
2/19/2024
Almirall S.A., a global pharmaceutical company dedicated to medical dermatology, announced that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.
-
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
12/12/2023
Almirall, S.A., a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.
-
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
11/14/2023
Almirall S.A. and Absci Corporation announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.
-
Almirall’s Nine-month 2023 Results:
11/9/2023
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.
-
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
10/13/2023
Almirall S.A., a global biopharmaceutical company focused on medical dermatology, announced the presentation of new data on lebrikizumab through 18 abstracts, including two oral presentations at the European Academy of Dermatology and Venereology Congress held in Berlin from October 11th to 14th.
-
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis
10/11/2023
Almirall S.A., a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that underscores its commitment to advancing the wellbeing of psoriasis patients and their families through treatments and cutting-edge research.
-
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
7/24/2023
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.
-
Almirall’s First Quarter 2023 Results
5/8/2023
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results.
-
Almirall’s Nine-month 2022 Results
11/10/2022
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.
-
Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc
9/29/2022
Simcere Pharmaceutical Group, an innovation and R&D-driven pharmaceutical company, and Almirall S.A., a global biopharmaceutical company focused on skin health; announced that they have entered into an exclusive licensing agreement for Simcere's IL-2 mutant fusion protein autoimmune drug candidate, SIM0278.
-
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
9/29/2022
Almirall S.A. and Simcere Pharmaceutical Grou announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein autoimmune drug candidate, SIM0278.
-
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
5/19/2022
Evotec SE and Almirall S.A., a global biopharmaceutical company focused on skin health, announced a multi-target alliance in Medical Dermatology.
-
Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
5/9/2022
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its Q1 2022 financial results.
-
Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers
2/21/2022
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2021 financial results.
-
Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall
2/21/2022
Dr. Jorge Gallardo Ballart has announced in the Board of Directors' session on Friday 18th February, his intention to retire from his positions of Chairman of the Board of Directors and Board member with effect as of the end of the General Shareholders Meeting of Almirall, S.A. that will take place next 6 May 2022.
-
Almirall delivers robust H1 performance and increases full-year guidance
7/26/2021
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its H1 2021 financial results.
-
Almirall's solid core business Q1 performance boosted by Growth drivers momentum
5/10/2021
Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year)
-
Almirall's 2020 Full-Year Results
2/22/2021
Almirall appointed Gianfranco Nazzi as the new CEO, effective May 1, 2021. Mr. Nazzi will bring continuity to the strategy as the business prepares for important launches to support future growth prospects
-
Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis
2/17/2021
Almirall S.A., a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora® Cream for treatment of plaque psoriasis.